[1] Regad T. Targeting RTK signaling pathways in cancer[J]. Cancers(Basel),2015, 7: 1758-1784. [2] Chabot T, Cheraud Y, Fleury F. Relationships between DNA repair and RTK-mediated signaling pathways[J]. Biochim Biophys Acta Rev Cancer, 2021, 1875:188495. doi: 10.1016/j.bbcan.2020.188495. [3] Won E, Basunia A, Chatila WK, et al. Efficacy of combined VEGFR1-3, PDGFα/β, and FGFR1-3 blockade using nintedanib for esophagogastric cancer[J]. Clin Cancer Res, 2019, 25:3811-3817. [4] Adrain C, Freeman M. Regulation of receptor tyrosine kinase ligand processing[J]. Cold Spring Harb Perspect Biol, 2014, 6: a008995. doi: 10.1101/cshperspect.a008995. [5] Liu L, Yu XZ, Li TS, et al. A novel protein tyrosine kinase NOK that shares homology with platelet- derived growth factor/fibroblast growth factor receptors induces tumorigenesis and metastasis in nude mice[J]. Cancer, 2004, 64:3491-3499. [6] Huang Z, Ma N, Xiong YL, et al. Aberrantly high expression of NOK/STYK1 is tightly associated with the activation of the AKT/GSK3beta/N-cadherin pathway in non-small cell lung cancer[J]. Onco Targets Ther, 2019, 12:10299-10309. [7] Zhou JP, Wang F, Liu BL, et al. Knockdown of serine threonine tyrosine kinase 1(STYK1) inhibits the migration and tumorigenesis in glioma cells[J]. Oncology, 2017, 25: 931-937. [8] Zhao YF, Yang L, He J, et al. STYK1 promotes Warburg effect through PI3K/AKT signaling and predicts a poor prognosis in nasopharyngeal carcinoma[J]. Tumour Biol, 2017, 39:1010428317711644. doi: 10.1177/1010428317711644. [9] Suplatov D, Kopylov K, Sharapova Y, et al. Human p38α mitogen-activated protein kinase in the Asp168-Phe169-Gly170-in(DFG-in) state can bind allosteric inhibitor Doramapimod[J]. J Biomol Struct Dyn, 2019,37:2049-2060. [10] Narayan B, Fathizadeh A, Templeton C, et al. The transition between active and inactive conformations of Abl kinase studied by rock climbing and Milestoning[J]. Biochim Biophys Acta Gen Subj, 2020, 1864:129508. doi:10.1016/j.bbagen.2019.129508. [11] 彭文, 张小猛, 张仓, 等. 靶向非活性激酶DFG-out变构结合位点的研究进展[J]. 中国新药杂志,2012,21: 890-895. [12] Hou SQ, Liu L. NOK mediated mitogenic signaling is altered by P203L and V395I mutations[J]. Frontiers Biosci, 2015, 20: 1179-1189. [13] 刘斌,刘力. NOK癌基因对人胚肾293T细胞周期G1/S期的影响及其作用机制[J]. 基础医学与临床, 2014, 34: 470-474. |